Stockreport

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF – Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from pivotal Phase 3 [Read more]